| 1. |
Zhu L, Song X, Tang J, et al.Huntingtin-associated protein 1:a potential biomarker of breast cancer[J].Oncol Rep, 2013, 29(5):1881-1887.
|
| 2. |
Beslija S, Bonneterre J, Burstein HJ, et al.Third consensus on medical treatment of metastatic breast cancer[J].Ann Oncol, 2009, 20(11):1771-1785.
|
| 3. |
Li WJ, Zhong SL, Wu YJ, et al.Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel-and adriamycin-resistant breast cancer cell lines[J].Mol Biol Rep, 2013, 40(11):6143-6150.
|
| 4. |
Li XJ, Ji MH, Zhong SL, et al.MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1[J].Arch Med Res, 2012, 43(7):514-521.
|
| 5. |
Nahta R, Yu D, Hung MC, et al.Mechanisms of disease:understanding resistance to HER2-targeted therapy in human breast cancer[J].Nat Clin Pract Oncol, 2006, 3(5):269-280.
|
| 6. |
Mimeault M, Hauke R, Batra SK.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies[J].Clin Pharmacol Ther, 2008, 83(5):673-691.
|
| 7. |
Wolmark N, Wang J, Mamounas E, et al.Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J].J Natl Cancer Inst Monogr, 2001, 2001(30):96-102.
|
| 8. |
Guarneri V, Broglio K, Kau SW, et al.Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J].J Clin Oncol, 2006, 24(7):1037-1044.
|
| 9. |
Rastogi P, Anderson SJ, Bear HD, et al.Preoperative chemotherapy:updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J].Clin Oncol, 2008, 26(5):778-785.
|
| 10. |
Mauriac L, Macgrogan G, Avril A, et al.Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm:a unicentre randomized trial with a 124-month median follow up.Institut Bergonié Bordeaux Groupe Sein (IBBGS)[J].Ann Oncol, 1999, 10(1):47-52.
|
| 11. |
Powles TJ, Hickish TF, Makris A, et al.Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer[J].J Clin Oncol, 1995, 13(3):547-552.
|
| 12. |
Smith IE, Walsh G, Jones A, et al.High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer[J].J Clin Oncol, 1995, 13(2):424-429.
|
| 13. |
Schwartz GF, Hortobagyi GN, Masood S, et al.Consensus conference committee proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA[J].Hum Pathol, 2004, 35(7):781-784.
|
| 14. |
Brito RA, Valero V, Buzdar AU, et al.Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases:The University of Texas M.D.Anderson Cancer Center experience[J].J Clin Oncol, 2001, 19(3):628-633.
|
| 15. |
Fayanju OM, Jeffe DB, Margenthaler JA.Occult primary breast cancer at a comprehensive cancer center[J].J Surg Res, 2013, 185(2):684-689.
|
| 16. |
Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al.Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer:A phaseⅡb/Ⅲtrial to investigate optimal duration of preoperative endocrine therapy[J].BMC Cancer, 2008, 8:62.
|
| 17. |
Perey L, Paridaens R, Hawle H, et al.Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors:final results of phaseⅡSwiss Group for Clinical Cancer Research Trial (SAKK 21/00)[J].Ann Oncol, 2007, 18(1):64-69.
|
| 18. |
Macedo LF, Sabnis GJ, Goloubeva OG, et al.Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model[J].Cancer Res, 2008, 68(9):3516-3522.
|
| 19. |
Leary AF, Drury S, Detre S, et al.Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance[J].Clin Cancer Res, 2010, 16(5):1486-1497.
|
| 20. |
Verma N, Swain SM.Bevacizumab and heart failure risk in patients with breast cancer:A thorn in the side?[J].J Clin Oncol, 2011, 29(6):603-606.
|
| 21. |
Choueiri TK, Mayer EL, Je Y, et al.Congestive heart failure risk in patients with breast cancer treated with bevacizumab[J].J Clin Oncol, 2011, 29(6):632-638.
|
| 22. |
Jiang ZF, Cristofanilli M, Shao ZM, et al.Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triplenegative (CBCSG004):a multicenter, double-blind, prospective trial[J].Ann Oncol, 2013 Jul 14[.Epub ahead of print].
|
| 23. |
Perou CM, Sørlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J].Nature, 2000, 406(6797):747-752.
|
| 24. |
Sørlie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci U S A, 2001, 98(19):10869-10874.
|
| 25. |
Calza S, Hall P, Auer G, et al.Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J].Breast Cancer Res, 2006, 8(4):R34-R43.
|
| 26. |
Rouzier R, Perou CM, Symmans WF, et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J].Clin Cancer Res, 2005, 11(16):5678-5685.
|
| 27. |
Singh G, Kumar P, Parshad R, et al.Role of color Doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy[J].Eur J Radiol, 2010, 75(2):e158-e162.
|
| 28. |
Croshaw R, Shapiro-Wright H, Svensson E, et al.Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients[J].Ann Surg Oncol, 2011, 18(11):3160-3163.
|
| 29. |
徐民, 纪建松, 卢陈英, 等.多层螺旋CT对进展期乳腺癌新辅助化疗的疗效评估[J].医学影像学杂志, 2012, 22(10):1677-1680.
|
| 30. |
Duch J, Fuster D, Muñoz M, et al.18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer[J].Eur J Nucl Med Mol Imaging, 2009, 36(10):1551-1557.
|
| 31. |
唐金海, 姚宇锋.早期乳腺癌的诊断和外科治疗进展[J].中国普外基础与临床杂志, 2011, 18(9):913-916.
|
| 32. |
Chen JH, Feig B, Aqrawal G, et al.MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy[J].Cancer, 2008, 112(1):17-26.
|
| 33. |
Craciunescu OI, Blackwell KL, Jones EL, et al.DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia:a pilot study[J].Int J Hyperthermia, 2009, 25(6):405-415.
|
| 34. |
汪晓红, 彭卫军, 信超, 等.动态增强MRI监测乳腺癌新辅助化疗疗效的应用价值[J].中华肿瘤杂志, 2010, 32(7):539-543.
|
| 35. |
Ring AE, Smith IE, Ashley S, et al.Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer[J].Br J Cancer, 2004, 91(12):2012-2017.
|
| 36. |
Prati R, Minami CA, Gornbein JA, et al.Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy[J].Cancer, 2009, 115(6):1194-1202.
|
| 37. |
Sánchez-Muñoz A, Pérez-Ruiz E, Jiménez B, et al.Targeted therapy of metastatic breast cancer[J].Clin Transl Oncol, 2009, 11(10):643-650.
|
| 38. |
Ross JS, Slodkowska EA, Symmans WF, et al.The HER-2 receptor and breast cancer:ten years of targeted anti-HER-2 therapy and personalized medicine[J].Oncologist, 2009, 14(4):320-368.
|
| 39. |
Vrbic S, Pejcic I, Filipovic S, et al.Current and future anti-HER2 therapy in breast cancer[J].J BUON, 2013, 18(1):4-16.
|
| 40. |
Sevcikova K, Vertakova-Krakovska B, Spanik S, et al.Neoadjuvant treatment in patients with HER2-positive breast cancer[J].ISRN Oncol, 2013, 2013:362467.
|
| 41. |
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al.2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA):an open-label, randomised controlled trial[J].Lancet, 2013, 382(9897):1021-1028.
|
| 42. |
NCCN乳腺癌临床实践指南(中国版)专家组.乳腺癌临床实践指南中国版[EB/OL].2011-04-10.http://www.nccnchina.org/nccn-guidelines-china.
|
| 43. |
Nahta R, Yu D, Hung MC, et al.Mechanisms of disease:understanding resistance to HER2-targeted therapy in human breast cancer[J].Nat Clin Pract Oncol, 2006, 3(5):269-280.
|
| 44. |
Price-Schiavi S, Jepson S, Li P, et al.Rat Muc4(sialomucin com-plex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, potential mechanism for herceptin resistance[J].Int J Cancer, 2002, 99(6):783-791.
|
| 45. |
Slamon D, Eiermann W, Robert N, et al.PhaseⅢrandomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu-positive early breast cancer patients:BCIRG 006 study[J].Cancer Res, 2009, 69(24):Supplement 3.
|
| 46. |
Buzdar AU, Ibrahim NK, Francis D, et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J].J Clin Oncol, 2005, 23(16):3676-3685.
|
| 47. |
Buzdar AU, Valero V, Ibrahim NK, et al.Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent herceptinin human epidermal growth factor receptor 2-positive operable breast cancer:an update of the initial randomized study population and data of additional patients treated with the same regimen[J].Clin Cancer Res, 2007, 13(1):228-233.
|
| 48. |
Baselga J, Bradbury I, Eidtmann H, et al.Lapatinib with herceptin for HER2-positive early breast cancer (NeoALTTO):a randomised, open-label, multicentre, phase 3 trial[J].Lancet, 2012, 379(9816):633-640.
|
| 49. |
Prowell TM, Pazdur R.Pathological complete response and accelerated drug approval in early breast cancer[J].N Engl J Med, 2012, 366(26):2438-2441.
|
| 50. |
Gianni L, Pienkowski T, Im YH, et al.Efficacy and safety of neoadjuvant pertuzumab and herceptinin women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere):a randomised multicentre, open-label, phase 2 trial[J].Lancet Oncol, 2012, 13(1):25-32.
|
| 51. |
Gianni L, Eiermann W, Semiglazov V, et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the Noah trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet, 2010, 375(9712):377-384.
|
| 52. |
Slamon D, Eiermann W, Robert N, et al.Breast cancer international research group.Adjuvant herceptin in HER2-positive breast cancer[J].N Engl J Med, 2011, 365(14):1273-1283.
|
| 53. |
Farolfi A, Melegari E, Aquilina M, et al.Trastuzumab-induced cardiotoxicity in early breast cancer patients:a retrospective study of possible risk and protective factors[J].Heart, 2013, 99(9):634-639.
|
| 54. |
Buzdar A.ACOSOG Z1041(Alliance):Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus Herceptin (FECPT) with paclitaxel plus Herceptin followed by FEC plus herceptin (PTFECT) in HER2 operable breast cancer[J].J Clin Oncol, 2013, ASCO abstr 502.
|
| 55. |
Franklin MC, Carey KD, Vajdos FF, et al.Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex[J].Cancer Cell, 2004, 5(4):317-328.
|
| 56. |
Agus DB, Gordon MS, Taylor C, et al.PhaseⅠclinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer[J].J Clin Oncol, 2005, 23(11):2534-2543.
|
| 57. |
Agus DB, Akita RW, Fox WD, et al.Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth[J].Cancer Cell, 2002, 2(2):127-137.
|
